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Abstract: Cyanobacteria are photosynthetic microorganisms that colonize diverse environments
worldwide, ranging from ocean to freshwaters, soils, and extreme environments. Their adaptation
capacities and the diversity of natural products that they synthesize, support cyanobacterial success
in colonization of their respective ecological niches. Although cyanobacteria are well-known for their
toxin production and their relative deleterious consequences, they also produce a large variety of
molecules that exhibit beneficial properties with high potential in various fields (e.g., a synthetic
analog of dolastatin 10 is used against Hodgkin’s lymphoma). The present review focuses on
the beneficial activities of cyanobacterial molecules described so far. Based on an analysis of
670 papers, it appears that more than 90 genera of cyanobacteria have been observed to produce
compounds with potentially beneficial activities in which most of them belong to the orders
Oscillatoriales, Nostocales, Chroococcales, and Synechococcales. The rest of the cyanobacterial orders
(i.e., Pleurocapsales, Chroococcidiopsales, and Gloeobacterales) remain poorly explored in terms of
their molecular diversity and relative bioactivity. The diverse cyanobacterial metabolites possessing
beneficial bioactivities belong to 10 different chemical classes (alkaloids, depsipeptides, lipopeptides,
macrolides/lactones, peptides, terpenes, polysaccharides, lipids, polyketides, and others) that exhibit
14 major kinds of bioactivity. However, no direct relationship between the chemical class and the
respective bioactivity of these molecules has been demonstrated. We further selected and specifically
described 47 molecule families according to their respective bioactivities and their potential uses
in pharmacology, cosmetology, agriculture, or other specific fields of interest. With this up-to-date
review, we attempt to present new perspectives for the rational discovery of novel cyanobacterial
metabolites with beneficial bioactivity.
Keywords: cyanobacteria; natural products; metabolites; biological activities; producers; chemical
classes
1. Introduction
Cyanobacteria belong to an ancient group of photosynthetic prokaryotes that present a very wide
range of cellular strategies, physiological capacities, and adaptations that support their colonization of
very diverse microenvironments worldwide. As a consequence, cyanobacteria occur in varied and
often extreme habitats and are then able to settle in diverse biotopes (e.g., marine, terrestrial, freshwater,
thermal springs) [1–3]. They are also well known for the production of a wide variety of bioactive natural
products, including some potent toxins (e.g., microcystins, anatoxins, and saxitoxins) [2,3]. Due to
the remarkable capability of cyanobacteria to proliferate and form toxic blooms that induce potential
human health consequences [4], numerous studies have been conducted to develop tools for the
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monitoring of such blooms [5,6] or effective strategies for the mitigation of their overgrowth [7]. On the
contrary, certain cyanotoxins could also constitute a promising opportunity for drug development
such as certain cancer therapies [8].
Two main aspects known as the chemical diversity and the related bioactivity have to be
considered when considering the application potential of natural products produced by cyanobacteria.
The chemical diversity of metabolites produced by these organisms has been well described and about
15 reviews have been already published in the past 20 years, dealing with their structural and chemical
diversity [9–14] or their respective biosynthetic pathways [15,16]. Beyond the notorious harmful effects
of cyanotoxins, other cyanobacterial natural products show a wide range of bioactivities that could be
potentially useful for diverse applications [17–21]. So far, among the existing reviews related to the
diversity of cyanobacterial metabolites, only one has addressed the relative taxonomical positions of
the different producing strains [9]. A few taxa appear to be especially prolific producers of a large
set of metabolites, while others still remain to be investigated. Recent genomics approaches and
genome sequencing have been important steps in the elucidation of the pathways implicated in the
biosynthesis of natural products. Their wide structural diversity has been described as a consequence
of the numerous biosynthetic pathways developed by cyanobacteria in order to produce these
metabolites [15]. Most of the active cyanobacterial molecules are considered as being produced either
through the non-ribosomal peptide (NRP) or the hybrid polyketide-NRP biosynthetic pathways [10],
or by the ribosomal synthesis of pro-peptides that are post-translationally modified (RiPP). Previous
genome analysis demonstrated that the diversity of the known metabolites is merely a fraction of
the true metabolic potential of cyanobacteria [15]. Concerning bioactivity, cyanobacteria have long
been a source of molecules with a potent nutritional property [18]. Aztec civilizations consumed
cyanobacteria (Spirulina) in their routine diet [22], and Chadian populations still use them as one of
their substantial food sources [23]. Besides nutritional and probiotic purposes [13,21], cyanobacteria are
well-known as an important source of metabolites with technological applications in the biotechnical
or pharmaceutical fields, which lead to an increase in interest in these research realms [10]. Most
bioactivities described to date are the antibacterial, antifungal, anti-cancerous, immunosuppressive,
anti-inflammatory, and anti-tuberculosis activities that have the potential to be used in fields such
as pharmacology, cosmetology, agriculture, the food industry, or as biofuel [17]. Cyanobacteria
cells represent a sustainable resource for biotechnology due to their photosynthetic, N-fixation, and
autotrophic capacities [17,18,24]. Due to the current increase in their pharmaceutical value and
in their application prospects for use in medicine or biotechnology, the exploration of uncovered
cyanobacterial taxa constitutes a promising strategy to efficiently explore the chemical diversity of
their bioactive compounds.
The present review globally and systematically describes current knowledge on the biological
activities described for cyanobacterial natural products, and, thanks to the construction of a specific and
freely available molecular database, regroups all information described so far concerning the chemical
structures, the producing organisms, and the various bioactivities of all the different cyanobacterial
metabolite families. This original material allows us to depict, from data based on exhaustive literature,
which kinds of bioactive metabolite are potentially produced by the different cyanobacterial taxa.
In this case, the producer organisms were considered at different taxonomic levels (family, order,
and genus) and are referenced according to their original habitats (freshwater, marine, and others).
The chemical diversity is described with respect to the different kinds of bioactivity and the potential
links between them are questioned, according to their potential or effective molecular mechanisms
of action. A specific focus on 47 cyanobacterial compounds presenting beneficial bioactivities is
detailed and discussed regarding their potential in pharmaceutical, cosmetical, biotechnical, and
agricultural applications, which opens new perspectives on the discovery of novel and potent bioactive
cyanobacterial molecules.
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2. Methods for Dataset Construction
A database was constructed using different search engines, notably PubMed and Google Scholar.
The keywords used were “cyanobacteria,” “metabolite” or “natural product,” “beneficial” and “activity,”
or “biological properties.” The database was first based on reviews and further completed with recent
publications dealing with the isolation of new compounds from cyanobacteria.
The main entries into the database were the names of the metabolites. To avoid bias in the
counting of metabolites, we stored all the data for each molecule and its variants as a “family.” In fact,
there are still no molecular classification references for a natural product description. As discussed by
Janssen [25], there is no standardized naming system along cyanobacterial metabolites, as in natural
product discovery in general, that could induce an underestimation of the real diversity of natural
products and to hide the potential link between their chemical structures, biosynthetic pathways, and
evolution routes. Thus, such a valuable classification of cyanobacterial metabolites is still needed,
notably in the current context of genomic and metabolomic development.
In our database, metabolites were grouped and classified based on different criterion, initially
selected by different authors [13,15,25]. First, they were classified according to their biosynthetic
pathways based on the genomic data reviewed by Dittmann et al. (e.g., microcystins, cryptophycins,
and aeruginosins) [15]. Secondly, when biosynthetic information was not available, metabolites were
classified, according to their structural homology, as proposed by Boudreau et al., [26], Janssen [25],
and Chlipala et al. [13], supposing that they might be sharing at least a similar, if not the same,
biosynthetic route (e.g., kulolide-family, aerucylamides, and cyanopeptolins). In most cases, metabolite
variants have a few differences occurring on a few residues and have conserved the specific structure
of their metabolite family. For example, the cyanopeptolin-like family, which contains, so far described,
139 variants, is comprised of a core structure of six amino acid residues and a variable side chain
containing between 1 and 3 residues. The sequence of the amino acids in the core structure is usually
composed with: Thr − [Leu|Arg|Tyr] − Ahp − [Ile|Phe|Thr|Leu|Val] − N-Me[Tyr|Phe] − [Val|Ile] (see
Supplementary Data S1). Some amino acids are variable (in brackets) and some others are identical
in the large majority of the variants, notably the 3-amino-6-hydroxy-2-piperidone (Ahp), and the
threonine (Thr) that support the side chain and close the cycle with an ester bond linkage (S1) [13].
The data collected were then classified depending on the chemical class of the compound, the
chemical structure, and the strain producing the metabolites with all the taxonomic information
(species, genus, family, and order), in accordance with Komarek et al. (2014) [27]. In addition, we
compiled the demonstrated activities for the purified compounds. Fourteen classes of activity were
mostly tested through the literature: lethality (against brine shrimp, and other small invertebrates),
neurotoxicity, hepatotoxicity, dermal toxicity, cytotoxicity, anti-inflammatory activity, antioxidant
activity, antiviral, antibacterial, antifungal, antialgal, antiprotozoal, serine protease inhibition, and
other types of enzyme inhibition.
Additionally, 670 publications were analyzed, dating from the 1970s until today (April 2019).
Around 1630 unique molecules have been reported so far and were grouped in 260 families of
metabolites (see Supplementary Data S2). To validate the knowledge depth of our work, a rarefaction
curve of the number of molecule families was constructed using the number of analyzed publications
(Figure 1).
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supports the postulation of the exhaustiveness of the present database. 
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The Oscillatoriales produces the largest number of metabolite families (153 families, 46.5%). The 
strains belonging to the Nostocales are also considerable producers of metabolites with 98 families 
(29.7%). The other main producers are the strains belonging to Chroococcales and Synechococcales, 
which exhibit, respectively, 34 and 31 described molecule families (10.3% and 9.4%). It is interesting 
that, except for these four orders, the others (i.e., Pleurocapsales, Chroococcidiopsales, 
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dominant cyanobacteria of the assemblage but could not accurately determine which one of them 
produces which molecule [28–40]. Tidgewell et al. (2010) [9] also identified the prevalence of marine 
cyanobacterial products within Oscillatoriales and Nostocales with 58% and 24% of the isolated 
molecules, respectively. Within Oscillatoriales, members of the genus Lyngbya, and, notably, Lyngbya 
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3. Taxonomy of the Producing Strains
The 260 families of molecules were attributed to cyanobacteria at their different taxonomic levels
(order, family, and genus) (Figure 2). Some families of compounds can be produced by different strains
and, thus, occur at different taxonomical levels. For example, microcystins are produced by various
strains belonging to seven different genera, five families, and three orders.
The Oscillatoriales produces the largest number of metabolite families (153 families, 46.5%).
The strains belonging to the Nostocales are also considerable producers of metabolites with 98 families
(29.7%). The other main producers are the strains belonging to Chroococcales and Synechococcales,
which exhibit, respectively, 34 and 31 described molecule families (10.3% and 9.4%). It is interesting
that, except for these four orders, the others (i.e., Pleurocapsales, Chroococcidiopsales, Gloeobacterales,
and Spirulinales) remain weakly represented in the database: less than five families of metabolite have
been reported so far for all of them.
Some metabolites have been isolated from cyanobacterial assemblages without accurate identification
of the producer organisms. For these cases, the authors identified the genera of the two dominant
cyanobacteria of the assemblage but could not accurately determine which one of them produces which
molecule [28–40]. Tidgewell et al. (2010) [9] also identified the prevalence of marine cyanobacterial
products within Oscillatoriales and Nostocales with 58% and 24% of the isolated molecules, respectively.
Within Oscillatoriales, members of the genus Lyngbya, and, notably, Lyngbya majuscula produce the
highest number of metabolites. This benthic genus is widely spread through the tropical marine
ecosystem and has been widely studied because of its toxicity and implication in many dermatitis
cases around the world [41,42]. A number of studies have been conducted on the Lyngbya genus,
and a high number of new metabolites have been described. In fact, Lyngbya is, to date, the most
productive genus of bioactive cyanobacterial compounds (Figure 2B). Recent studies showed that
Lyngbya is polyphyletic [27,43] and using polyphasic approaches, Lyngbya has been split into four new
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genera: Moorea [44], Okeania [45], Limnoraphis [46], and Microseira [47]. Some marine strains previously
identified morphologically as Lyngbya majuscula and Lyngbya sordida were, therefore, renamed as
Moorea producens, and some strains of Lyngbya bouillonii were renamed to Moorea bouillonii on the basis
of molecular and phylogenetic analyses [44]. In the same way, some freshwater strains morphologically
identified as Lyngbya wollei were separate from the Lyngbya genus and described as Microseira wollei
after analysis of their phylogenetic position [47].
According to this information, we decided to present the number of metabolite families produced
by the Lyngbya and the Moorea genera together (reported as Lyngbya-Moorea in Figure 2B), given that
the majority of families isolated from Lyngbya species were reported to be from Lyngbya majuscula
(46 of 78 described from all the Lyngbya) or from Lyngbya spp. strains sampled from tropical marine
environments (22 of 78), as described for the Moorea genus and were possibly misidentified with regard
to this newly described genus [44].
At the family level, the main producers of known bioactive compounds belong to Oscillatoriaceae
(30.3%, producing 122 families of compounds), followed by Nostocaceae and Microcoleaceae (17.2%
and 10.9% for 69 and 48 molecule families, respectively) (Figure 2A). At the genus level (Figure 2B),
Lyngbya-Moorea exhibits the highest number of isolated compounds (85 families of metabolites
representing 20.6%), in accordance with the perceived richness of production for the Lyngbya genus due
to its polyphyletic status [48]. Nostoc is the second most prolific genus of bioactive compound families
with 50 isolated families so far (12.1% of the total number of families of metabolites). The other most
important genera are Anabaena, Oscillatoria, and Microcystis (with 32, 31, and 27 families of molecules,
respectively, representing 7.8%, 7.5%, and 6.6%) (Figure 2B).
When looking at the habitats of these cyanobacteria, a large number of compounds were isolated
from marine environments (148 families of metabolite in the database, which means 53% of the
families of metabolites) in comparison to the number of strains isolated from freshwater environments
(77 families of metabolites, 27.6%) (Figure 2B). However, this difference might be at least partly
due to the high number of compounds isolated from the marine species Lyngbya majuscula-Moorea
producens (49 families of molecules, 18.8% of the families in the database) and to the existence of various
research programs focused on marine species (e.g., the Panama International Cooperative Biodiversity
Group, ICBG).
Overall, we observed that diversity at the genus level is important, as illustrated by the 90 different
genera present in the database. Moreover, 65 different genera have been reported to produce less than
four molecules (Figure 2B). We also noticed that five molecules were isolated from Lyngbya/Schizothrix
assemblages and five others from unidentified strains of cyanobacteria (Figure 2B). Thus, at the genus
level, the diversity of producers is large with a high number of genera studied (90 different genera).
Nevertheless, these genera generally belong to the same orders (e.g., Oscillatoriales, Nostocales,
Synechococcales, and Chroococcales) while some orders were not studied. For example, among the
Pleurocapsales order, only four genera have been reported to produce metabolites. As a result, the
covered diversity appears not to be exhaustive and can still be increased.
According to Shih et al. (2013) [49], the genomic potential of cyanobacteria to produce secondary
metabolites is high with more than 70% of the studied strains presenting non-ribosomal peptide synthase
(NRPS) or polyketide synthase (PKS) gene clusters in their genomes. In particular, they identified
one strain belonging to the Fischerella genus (Fischerella sp. PCC 9339) that exhibits 22 NRPS/PKS
clusters in its genome. On the contrary, only five compound families have been isolated from the
genus Fischerella so far and are listed on the present database. Moreover, it is interesting to note that,
among the 126 strains analyzed by Shih et al. (2013) [49], only 14 were formally reported to produce
characterized metabolites.
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In addition, the best producer genus, Lyngbya-Moorea, remains rarely studied at the genomic
level: four genomes are available in the Genbank database and another three are available on the
Microscope platform [50]. Considering the number of compounds isolated from the Lyngbya-Moorea
genus (85 compound families), most of the links between the identified molecules and the responsible
biosynthetic gene clusters remain to be characterized. We also compared our collected data with those
reported by Dittman et al. (2015) [15] in order to determine when the isolated molecule families are
linked with a specific and identified biosynthetic gene cluster. This review showed that less than
20% of the molecule families from the database are associated with specific identified biosynthetic
gene clusters. Thus, the biosynthetic pathways of a large majority of compounds is still unknown
as well as the regulation mechanisms controlling their production. Therefore, these observations
highlight part of the remaining possibilities for the discovery of new molecules, gene production, and
biosynthetic pathways.
4. Chemical Diversity and Bioactivity of Natural Products from Cyanobacteria
Each of the 260 families of compounds was classified by chemical classes and bioactivity (Figures 3
and 4). The 260 families of compounds were classified by their chemical classes, and 10 different
classes were listed: alkaloids, depsipeptides, lipopeptides, macrolides/lactones, peptides, terpenes,
polysaccharides, lipids, polyketides, and others (Figure 3). Of the 260 metabolite families, 66 belong to
the peptide class. Together with the depsipeptide and lipopeptide classes, they represent 133 families of
compounds (51%) derived from peptides. This is not surprising, regarding the diversity of biosynthetic
pathways described in cyanobacteria: NRPS (non-ribosomal peptide synthase), PKS (polyketide
synthase) and RiPPs (ribosomally synthesized and post-translationally modified peptides) with the
ability to produce a wide range of metabolites and notable peptides [15] (Figure 3).
Fourteen major activities have been listed from the literature (lethality, neurotoxicity, hepatotoxicity,
dermaltoxicity and cytotoxicity, anti-inflammatory, antioxidant, antiviral, anti-microalgal, antibacterial,
antifungal, and antiprotozoal activities as well as protease and enzyme inhibition activities). Cytotoxic
activity against various cell lines is the most frequently detected type of bioactivity with up to
110 families of the 260 listed. On the other hand, lethality and the antibacterial activities have been
detected for 54 and 43 compound families, respectively (Figure 4).
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Figure 3. Classification of the 260 cyanobacterial metabolite families according to their respective chemical classes. All the molecules have been classified into these
different classes according to their respective structural characteristics. For example, the depsipeptides are a class of peptides containing an ester bond and macrolides
are molecules exhibiting a macrocycle and one or more lactone functions. Some examples of cyanobacterial molecules belonging to these classes are illustrated.
Hapalindole A (alkaloids), Oscillapeptin A (depsipeptides), Minutissamide A (lipopeptides), Caylobolide B (macrolides/lactones), Anabaenopeptin E (peptides),
β-carotene (terpenes), Cyclodextrin phosphate (polysaccharides), Lyngbic acid (lipids), and Cylindrocyclophane A (polyketides). The main characteristics of each
chemical class are highlighted in red. All the structures were obtained from the ChEMBL Database (https://www.ebi.ac.uk/chembl/).
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of l c les have been tested gainst different targets ranging from a specific cellular mechanism
to a entire organism. For example, the inhibitor activity of proteases a d other enzymes was
shown to target enzymatic processes when the lethality and antimicrobial activity were tested against
whole organisms. The lethality tests were generally realized against small invertebrates such as
the brine shrimp crustacean Artemia salina, the gastropod mollusk Biomphalaria glabrata, and the
crustacean Thamnocephalus platyurus. The present analysis confirms preceding observations (i.e., that
cytotoxicity is the most commonly detected activity, followed by lethality and antibacterial activity).
Some activities were detected only for a restricted number of compounds: dermaltoxicity concerned
only two families of metabolites (aplysiatoxins and lyngbyatoxins) [51,52], hepatotoxicity was observed
for three families (cylindrospermopsins, microcystins, and nodularins) [53–55], antioxidant and
anti-inflammatory activities were observed for four (carotenoids, chlorophylls, mycosporine-like amino
acids, and phycocyanins) [56–59], and seven metabolite families (coibacins, honaucins, aeruginosins,
malyngamides, phycocyanin, scytonemin, and tolypodiol) [60–66], respectively. Nevertheless, there
are only a few examples of these activities being tested by authors in comparison with cytotoxicity
and lethality, which have been investigated far more regularly. In terms of anti-inflammatory activity,
all seven tested molecules cited a ove were positive for this type of activit , and 53% of the studied
molecule families have been tested for cyt toxic activity, whi e only 2.7% have een tested for
anti-inflammatory activity. In parallel, some of thes metabolite families can exhibit mor than one
activity. In fact, a total of 362 activities have been detected for the whole of the 260 metabolite families.
Focusing on the chemical classes, it ap rs t t t r is no specific indication that one chemical
class exhibits specific activities with regard to other classes. The results from the review showed that
the polysaccharide class presents only two tested activities (enzyme inhibition and antiviral activity),
but only three types of polysaccharides isolated from cyanobacteria have been observed so far (calcium
spirulan, cyclodextrins, and iminotetrasaccharide) [67–69]. Five chemical classes (the alkaloids, the
depsipeptides, the lipopeptides, the macrolides, and the peptides) seem to present a remarkably large
set of activities. When comparing the number of detected activities with the number of molecules
belonging to each chemical class, the most bioactive molecules were shown to be the alkaloids, the
lipopeptides, and the polyketides, which exhibit respectively 2.2, 1.9, and 1.8 activities per molecule
on average.
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Figure 5. Classification of the 260 metabolite families according to their respective activities and
chemical classes. The number of metabolite families is symbolized by the disc diameters, for each
activity and each chemical class. For example, the first circle represents the number of alkaloids that
exhibit a hepatotoxic activity (in this case, one family of metabolites). Colors correspond to the different
categories of activity targets. For example, cytotoxicity and hepatotoxicity are tested in vitro against
cell lines while neurotoxicity, antioxidant, and anti-inflammatory activities can be biochemically tested
for specific cellular mechanisms (such as the sodium influx, the scavenging of ROS (reactive oxygen
species), and the inhibition of cytokines).
These observations highlight a bias in the bioactivities searched from the isolated molecules. First,
reported activities were those that researchers decided to test. Thus, the metabolite bioactivity profile
could be underestimated because of the number of tests realized and remains the main limitation for
the description of the potential applications of the bioactive molecules. In addition, there is still no
consensus concerning the dose and dilution threshold that should be considered for each individual
bioactivity test. In some cases, the concentration difference, used to determine if two distinct molecules
are active, is important. For example, odoamide [70], which is a cyclic depsipeptide member of the
aurilides family, and scytoscalarol [71], a sesterterpene, have both been described as being “cytotoxic.”
However, their respective IC50 values appear to be very different: 26.3 nM against HeLa S3 human
cervical cancer cells for odoamide and 135 µM against Vero cells for scytoscalarol, which represents a
concentration difference of 500 times between their respective inhibition potentials. Furthermore, tests
can be realized against several cell lines and strains presenting different sensitivity responses, which
limit the comparison between results.
With 10 chemical classes and 14 types of bioactivity, the cyanobacterial metabolites are diverse and
highly active. However, half of the families of metabolites listed in the database are peptides or peptide
derivatives. This could be due to the importance of the peptide biosynthetic pathway (NRPS, PKS, and
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RiPPs) or the extraction methods used, which might favor peptide extraction. We did not observe a
link between chemical classes and activities, but this observation must be considered carefully with
regard to the low number of investigated molecules in some classes (i.e., polyketides, polysaccharides,
and terpenes). The most frequently detected activity for cyanobacterial metabolites is cytotoxicity
(42% of the metabolite families), whereas antioxidant or anti-inflammatory activities were detected for
only 1.5% and 2.7% of the families. This imbalance is due to the frequency at which tests were carried
out. In fact, cytotoxicity was tested for 53% of the molecules, while anti-inflammatory activity was
only tested in 2.7%. This observation may reflect the research inclination to find new pharmaceutical
compounds, notably cytotoxic compounds that are usable in cancer therapy, and suggests the potential
for the discovery of new activities for application in other fields.
5. Beneficial Activities of Natural Products Produced by Cyanobacteria
In this review, we further considered and developed 47 examples of molecules that are considered
as exhibiting potential beneficial activities for several purposes. The 260 families of compounds could
have a wide range of applications, e.g., agriculture, pharmacology, cosmetology, or in the food industry.
For potential applications in agriculture, cyanobacterial compounds could be useful for alternative soil
fertilization methods and as chemical pesticides [18]. The potential pharmaceutical applications of
cyanobacterial metabolites include the development of new antibiotics, antibacterial drugs, or antiviral
drugs [21]. Metabolite families were selected because of their specific features described below in each
bioactivity-related section.
5.1. Antimicrobial Activity
Antimicrobial compounds that do not present toxic effects are particularly of interest for
applications in the food industry in order to clean processing equipment or for food preservation [72,73].
Cyanobacteria produce 85 families of metabolites isolated from various strains, which display potent
antimicrobial activity (representing a third of the 260 molecule families listed in the database) [18].
Below, we summarize the different antimicrobial metabolites (organized by type of antimicrobial
activity) that have been isolated from cyanobacteria so far and the corresponding relevant information
(see Tables 1–5). We also detail some examples of specific molecules that exhibit interesting bioactivity
profiles such as the selective profile for their activity, which present broad-spectrum action together
with the absence of associated cytotoxicity.
5.1.1. Antibacterial Activity
Among the metabolite families listed, 43 molecules exhibit antibacterial activity, which represents
17% of the families. These components were, in general, tested against different types of bacteria:
GRAM-negative, GRAM-positive mycobacteria, and cyanobacteria.
Among the 43 molecules, 22 are also cytotoxic and 16 present lethal activity against small
invertebrates. Only three of them—eucapsitrione, kulolide-like molecules, and abietic acid—may have
specific antimicrobial activity and no activity against other microorganisms.
Eucapsitrione and kulolide-like molecules (Table 1, details available in Supplementary Data S3)
show antibacterial activity (against Mycobacterium tuberculosis) without inhibitory activity against the
yeast Candida albicans [74,75]. Eucapsitrione is a anthraquinone derivative molecule isolated from
the cyanobacterium Eucapsis sp. (UTEX 1519) [74]. This phenolic compound family is well-known
in plants and some microorganisms, and has demonstrated a large range of bioactivities, including
antimicrobial, antioxidant, anti-inflammatory, and potent anticancer properties [76–79]. This opens up
other perspectives and applications for these anthraquinone derivatives isolated from cyanobacteria,
such as eucapsitrione. However, so far, its other potential bioactivities have not been tested.
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Table 1. Antibacterial molecules extracted from the database and discussed in this review.
Molecule Family Chemical Classes Activity Producing Organisms References
Eucapsitrione Anthraquinone derivative
-Antibacterial
-No antifungal
-Cytotoxic
Eucapsis sp. UTEX 1519 [74]
Kulolide-like analogs Depsipeptide
-Antibacterial
-No antifungal
-Antiprotozoal
-Lethal
-Cytotoxic
-VGSC (Voltage Gate Sodium
Channel) activation
Lyngbya majuscula,
Rivularia sp.,
Moorea producens,
Okeania sp.,
Symploca hydnoides,
Oscillatoria margaritifera
[26,75,80–90]
Abietic acids Terpene
-Antibacterial
-No lethality
-No antialgal
Plectonema radiosum LEGE 06105,
Nostoc sp. LEGE 06077 and LEGE 07365,
Chroococcidiopsis sp. LEGE 06174,
Synechocystis sp. LEGE 06079,
Synechocystis salina LEGE 06099,
Leptolyngbya ectocarpi LEGE 11425,
Nodosilinea sp. LEGE 13457,
Nodosilinea nodulosa LEGE 07084
[91]
Hapalindole-like Alkaloid
-Antibacterial
-Antifungal
-Antialgal
-Cytotoxic
-Insecticidal
-Lethal activity
-Reverse multidrug resistance (MDR)
-VGSC modulator
Hapalosiphon fontinalis,
Westiellopsis sp.,
Fischerella musicola,
Hapalosiphon welwitschii,
Westiella intricata,
Fischerella ambigua,
Hapalosiphon delicatulus,
Hapalosiphon hibernicus,
Westiellopsis prolifica,
Fischerella sp.,
Hapalosiphon laingii
[92–117]
More details about compound activities are available in Supplementary Data S3.
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Table 2. Antialgal molecules extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Cyanobacterin Lactone derivative
-Antialgal
-Anti-cyanobacterial
-Growth inhibition
Scytonema hofmanni UTEX 2349,
Nostoc linckia CALU 892 [118–121]
Fischerellins Polyketide
-Antialgal
-Anti-cyanobacterial
-Antifungal
-Lethal
-Growth inhibition
Fischerella musicola,
Fischerella sp.,
Fischerella ambigua,
Fischerella tesserantii
[122–125]
Westiellamide-like analogs Peptide
-Antialgal
-Anti-cyanobacterial
-No antifungal
-Lethal activity
-Cytotoxic
Westiellopsis prolifica EN-3-1,
Nostoc sp. 31,
Stigonema dendroideum IA-45-3,
Oscillatoria raoi TAU IL-76-1-2,
Nostoc spongiaeforme var. tenue str. Carmeli
[126–131]
Ambigols Alkaloid
-Antialgal
-Antibacterial
-Antifungal
-Antiprotozoal
-Lethal activity
-Cytotoxicity
-Enzyme inhibition
Fischerella ambigua 108b [132,133]
Schizotrin-like analogs Peptide
-Antialgal
-Antibacterial
-Antifungal
-Antiprotozoal
-Lethal activity
-Cytotoxicity
Schizothrix sp. TAU IL-82-2,
Lyngbya sp. 36.91,
Phormidium sp. LEGE 05292,
Tychonema sp. CCAP 1462/13
[134–141]
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The kulolide-like family includes 44 related molecules. Kulolide, which is the first molecule
of the family to be discovered, was isolated from a cephalaspidean mollusk Philinopsis speciosa [80].
Luesch and co-workers (2001) isolated the first cyanobacterial analogues of this family, naming
them the pitipeptolides, and proposed a cyanobacterial origin for kulolide itself [89]. All members
of the kulolide-like family share chemical similarities and can be categorized into two subgroups:
those containing 2,2-dimethyl-3-hydroxy-7-octynoic acid (Dhoya) and those containing 3-hydroxy-2-
methyl-7-octynoid acid (Hmoya) [26]. The same activities were not tested for all analogues, but some
of them have shown antibacterial, antiprotozoal, cytotoxic, and even lethal activities (Table 1).
The third example of a family of molecule presenting a specific anti-bacterial activity is that of
abietic acids (Table 1). Abietic acid is a terpene that is generally found in resin and used by conifers as
a defense metabolite [91]. It demonstrates anti-cyanobacterial activity against Synechococcus nidulans,
and seems to be non-toxic to Chlorella vulgaris and the brine shrimp Artemia salina (Table 1). It has been
suggested that its activity and defense mechanisms could be equivalent to those of coniferous plants,
i.e., trapping microorganisms or acting as allelochemical compounds. These non-toxic properties are
compelling for the development of specific anti-cyanobacterial products.
The hapalindole-like group is a family of alkaloids, which contains around 80 related
molecules [92–117] (Table 1). These metabolites were previously isolated from Hapalosiphon, Fischerella,
Westiellopsis, and Westiella genera. They show a wide range of activity, most notably, antibacterial
activity against 27 various bacterial strains, together with antifungal and antialgal activities. They are
also cytotoxic and exhibit additional insecticidal activity. Some of them were even able to reverse drug
resistance in cancer cell lines [97,116] (Table 1). They putatively exhibit modulatory activity on sodium
channels [95], which could explain their diverse bio-activities.
5.1.2. Antialgal Activity
Antialgal activity was tested generally against microalgae, and 10 families of metabolites were
shown to present such activity. Among these 10 families, four also exhibited anti-cyanobacterial
activity, and it can be supposed that these molecules may be acting against general photosynthesis
mechanisms. For example, cyanobacterins isolated from two strains, Scytonema hofmanni UTEX 2349
and Nostoc linckia CALU 892 [118,119], were shown to present significant antimicrobial activity directed
against a large panel of microalgal and cyanobacterial strains (Table 2). These compounds also inhibit
the growth of eight angiosperm plants, such as duckweed (Lemna genus), pea, corn, sorrel, black
bindweed, wild oat, and green foxtail [120] (Table 2). Gleason and Case (1986) showed that this activity
is due to the inhibition of the Hill reaction in photosystem II without inhibition of photosystem I [120].
Another example is the fischerellin family. These compounds were observed in four strains
belonging to the Fischerella genus. They show a wide range of activities comprising growth inhibition of
Lemna minor, antifungal and lethal activities, and antialgal and anti-cyanobacterial activities. Hagmann
& Jüttner (1996) showed that fischerellins A is an effective inhibitor of photosystem II [123] (Table 2).
The westiellamide-like analogs family comprise 12 related cyclic peptides isolated from five
strains belonging to four different genera (Table 2). The related molecules, known as the bistratamides,
were previously isolated from the ascidian Lissoclinum bistratum [142], and authors hypothesized a
cyanobacterial symbiont origin for these molecules [128]. This family of compounds have been shown
to have anti-algal and anti-cyanobacterial activities (Table 2), but they did not show any antifungal
activity against the yeast Saccharomyces cerevisiae [126–131]. Moreover, one of them, dendroamide
A, has shown the ability to reverse the multi-drug resistance of a human breast carcinoma cell
line (MCF-7/ADR) [126]. The MCF-7/ACR cell line overexpresses the P-glycoprotein pump, which
transports drugs outside of the cell, providing higher resistance to chemical treatment. Dendroamide A
is able to specifically inhibit the action of the P-glycoprotein pump, which allows the drug to penetrate
and lyse the cells, so it has potential anticancer applications.
Among the antialgal compounds, two have a remarkably broad spectrum of antimicrobial activities:
the ambigols and the schizotrin-like analogs families, both show antialgal, antibacterial, antifungal,
Mar. Drugs 2019, 17, 320 15 of 49
and antiprotozoal activities (Table 2). Three ambigol variants were isolated from Fischerella ambigua
strain 108b, while the schizotrin-like family includes 13 structurally related molecules isolated from
four different strains (Table 2). In addition to these antimicrobial activities, the ambigols also present
enzyme inhibition activity against cyclooxygenases and HIV-1 reverse transcriptase. The members
of the schizotrin-like family, the portoamides (isolated from Phormidium sp. LEGE 05292), have also
shown mitochondrial metabolism inhibition activity, which induces a further decrease in the cellular
ATP content in cells exposed to portoamides [140]. This property is also promising for the development
of drugs acting against tumors and cancers [143].
Via their main antialgal action (i.e., photosynthesis inhibition), the molecules have been shown to
present other potential uses and could be used as alternatives to chemical herbicides based on PSII
inhibition (e.g., 3-(3,4-dichlorophenyl)-1,1-dimethylurea, DCMU). These families of compounds could
be used to develop new algaecides and herbicides and/or to develop new pharmaceutical drugs.
5.1.3. Antifungal Activity
Twenty-eight families of compounds showed antifungal activities. Toxicity tests were carried
out against diverse fungal species, which are mostly pathogenic ones. Quite common ones include
Candida albicans, Saccharomyces cerevisiae, Penicillium notatum, and Aspergillus oryzae, and less common
ones include Trichophyton mentagrophytes and Ustilago violacea. Among these compounds, 11 showed
several other types of antimicrobial activity in addition to antifungal activity. Only two metabolite
families, hassallidins and lyngbyabellins, demonstrated specific antifungal activity without presenting
any antibacterial activity. The hassallidins are cyclic glycolipopeptides isolated from three strains
belonging to the Nostocales (Table 3). Four variants have been characterized so far [144–148], and the
non-ribosomal peptide gene cluster responsible for hassallidin biosynthesis has been identified. Thus,
the hassallidins cluster was detected by bioinformatics analysis of the genomes of four heterocytous
cyanobacteria, Aphanizomenon gracile, Cylindrospermopsis raciborskii, Nostoc sp., and Tolypothrix sp.,
and hassallidins production was confirmed by LC/MS analysis (Table 3). Recently, Pancrace et al.
(2017) identified the hassallidins gene cluster and characterized a new hassallidins variant from
Planktothrix serta (PCC 8927), which is a nitrogen-fixing, non-heterocytous forming strain [147]. They
concluded that the strain gain of the cluster occurred by horizontal transfer and, therefore, questioned
the natural product distribution and diversity among cyanobacteria.
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Table 3. Antifungal molecules extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Hassallidins Glycolipopeptide -Antifungal-No antibacterial activity
Hassalia sp. B02-07,
Anabaena sp. (SYKE 748A, 90y1998, 90M3, 299B,
258, SYKE763A, 0TU33S16, 0TU43S8, 1TU33S8,
1TU35S12, 1TU44S9, 1TU44S16, SYKE971/6,
NIVA-CYA269/2, NIVA-CYA269/6, XPORK5C,
XSPORK7B, XSPORK36B, XSPORK14D, BECID19),
Anabaena cylindrica Bio33
Cylindrospermopsis raciborskii (ATC-9502 & CS-505),
Aphanizomenon gracile Heaney/Camb 1986 140 1/1,
Nostoc sp. (159 & 113.5),
Tolypothrix sp. PCC 9009
Planktothix serta PCC 8927
[144–148]
Lyngbyabellins Depsipeptide
-Antifungal
-No antibacterial activity
-Lethal activity
-Cytotoxic
Lyngbya majuscula
Lyngbya sp.,
Lyngbya bouillonii
Moorea bouillonii
[149–156]
Micro-guanidines Guanidine derivative
-Antifungal
-No cytotoxicity
-No protease inhibition
Microcystis sp. TAU IL-306,
Microcystis aeruginosa TAU IL-374 [157–159]
Majusculamides Lipopeptide
-Antifungal
-Cytotoxic
-Immunosuppressive activity
-Actin filaments disrupting
-Anti-settlement activity
Lyngbya majuscula,
Lyngbya polychroa [160–166]
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The lyngbyabellins are cyclic depsipeptides. They were isolated from Lyngbya and Moorea
species (Table 3). Hectochlorin is the only member of the family that was tested for antibacterial and
antifungal activity, which showed no antibacterial activity but displayed antifungal activity against
Candida albicans [152]. The distinctive feature of the lyngbyabellins is that they can also disrupt
actin filaments. Luesch et al. (2000) [151] and Han et al. (2005) [150] showed that cells exposed
to Lyngbyabellin A and E lost their microfilament network, which caused cell cycle arrest at the
cytokinesis phase. Marquez et al. (2002) [152] showed that the same process appears with cells exposed
to hectochlorin. They also demonstrated that the molecule stimulates actin polymerization and then
induces cell cycle disorders.
Microguanidines are guanidine derivatives isolated from two strains of Microcystis (Table 3).
These molecules showed antifungal activity against Saccharomyces cerevisiae E4orf4 without cytotoxic
activity. This specificity could be of interest for the development of new antifungal products [158].
Majusculamides are lipopeptides produced by Lyngbya majuscula and Lyngbya polychroa. These
metabolites combine antifungal and cytotoxic activities with immunosuppressive and anti-settlement
properties [160–166]. Simmons et al. (2009) [165] also demonstrated the ability of majusculamides to
disrupt actin filaments that may explain these specific properties (Table 3).
5.1.4. Antiviral Activity
Viral diseases are one of the main health concerns around the world. According to the World
Health Organization (WHO), HIV and AIDS caused around one million deaths in 2017 [167]. We noted
that eight families of cyanobacterial compounds have shown antiviral activity. Antiviral activity was
generally determined by testing against the human immunodeficiency virus (HIV-1 or HIV-2) or the
Herpes simplex virus (HSV-1 or HSV-2). The aplysiatoxins showed activity against Chikungunya’s
virus (CHIKV) [168] (Table 4), but are also very active dermatotoxins [51,169] and tumor-promoting
molecules due to their capacity to activate protein kinase C (PKC), which is an enzyme that plays roles
in cell proliferation, differentiation, and apoptosis [168] (Table 4). Recently, Han et al., demonstrated
that two aplysiatoxin analogues showed the capability to inhibit the potassium channels [170], which
opens interesting perspectives for the study and use of these molecules for drug development.
Table 4. Antiviral molecules extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Aplysiatoxins Alkaloid
-Antiviral
-Dermatitis and swimmer’s
itch agents
-Cytotoxic
Lyngbya majuscula,
Schizothrix calcicola,
Oscillatoria nigro-viridis,
Trichodesmium erythaeum
[51,168,170–173]
Cyanovirin-N Protein
-Antiviral
-No cytotoxicity
-Stop fusion and
transmission of HIV-1 virus
Nostoc ellipsosporum
Cyanothece sp. [174–176]
Calcium spirulan Polysaccharide
-Antiviral
-No cytotoxicity
-Low anticoagulant activity
Arthrospira platensis [67,177,178]
Two other families of molecules have shown antiviral activity against a large panel of viruses.
The first one, cyanovirin-N analogs, have been isolated from Nostoc ellipsosporum [174] and Cyanothece
sp. [176] (Table 4). These molecules are proteins belonging to the lectins class because of their ability to
bind glycans. Cyanovirins show inhibitory activity against HIV-1, HIV-2, simian immunodeficiency
virus (SIV), feline immunodeficiency virus, HHV-6, and measles virus [174,175]. Also, they inhibit
Ebola and influenza viruses [176]. Nevertheless, cyanovirins are not active against some viruses, such
as human herpesvirus A (HHV-1), cytomegalovirus, and adenovirus type 5 [175]. Cyanovirins are
also non-cytotoxic for non-infected cells (at concentrations required for antiviral activity) [174,175]
(Table 4). In fact, cyanovirin-N binds gp120, which is a glycoprotein component of the HIV envelope.
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As a result, the molecule inhibits membrane fusion into target cells and stops virus transmission.
Calcium spirulan has been isolated from Arthrospira platensis (anc. Spirulina platensis) and is a
sulphated polysaccharide. It shows antiviral activity against a wide range of viruses including HIV-1,
HSV-1, the human cytomegalovirus (HCMV), measles virus, mumps virus, and influenza virus,
in addition to a low cytotoxicity against several cell lines (ID50 values between 2900 and 7900 µg/mL)
(Table 4) [67,178]. Furthermore, calcium spirulan seems inactive against Poliovirus and Coxsackievirus,
two non-enveloped viruses, which means that it likely has selective activity for enveloped viruses.
Hayashi et al. (1996) [67] also showed that this molecule inhibits virus penetration in targeted cells.
Other sulphated polysaccharides are known for their anticoagulant and antiviral activity, such as
heparin or dextran sulphate [179,180]. In comparison to these molecules, calcium spirulan showed
a lower anticoagulant activity and a longer half-life in blood [177], which confirms its promising
potential for the development of new specific antiviral drugs.
5.1.5. Antiprotozoal Activity (Against Malaria, Leishmaniosis, Chagas Disease)
The last kind of antimicrobial properties tabulated is antiprotozoal activity. Protozoans are
eukaryotic microorganisms, some of them have parasitic lifestyles and are well-known for their
involvement in human diseases such as Malaria, Leishmaniosis, Chagas’ disease, and Trypanosomiasis.
These diseases represent a huge problem in tropical countries where the parasite is transmitted
by mosquitoes. The WHO identified more than 210 million Malaria cases in 2016 [181]. Therein,
molecules with antiprotozoal activity are actively being sought in order to develop new drugs against
these diseases.
Table 5. Antiprotozoal molecules extracted from the database.
Molecule Family Chemical Classes Activity ProducingOrganisms References
Companeramides Depsipeptide
-Antiprotozoal
-No significant
cytotoxicity
Leptolyngbya sp. or
«Hyalidium» [29]
Hoshinolactam Lactam -Antiprotozoal-No cytotoxicity Oscillatoria sp. [182]
Dolastatins Peptide
-Antiprotozoal
-Lethal
-Cytotoxic
Lyngbya majuscula,
Symploca hydnoides,
Lyngbya sp.,
Symploca sp. VP642,
Lyngbya-Schizothrix
assemblage
[30,32,75,183–189]
From the review, 28 cyanobacterial metabolites showed antiprotozoal activities. Tests have
been conducted against several strains of Plasmodium falciparum (causative agent of Malaria),
Leishamania donovani (Leishmaniosis), Trypanosoma cruzi (Chagas’ disease), and Trypanosoma brucei
(Sleeping sickness). Among the 28 concerned families of molecules, 19 showed antiprotozoal activity
against drug-resistant strains, especially against chloroquine-resistant strains of Plasmodium falciparum
(see Table 5). Nevertheless, most of them are less active than the antibiotics currently used. For example,
companeramides are cyclic depsipeptides produced by a cyanobacterium previously identified as
Leptolyngbya sp. (now Hyalidium) [29] (Table 5). Companeramides showed antimalarial activity against
three strains of chloroquine-resistant Plasmodium falciparum. They also showed no significant cytotoxicity
against the cell lines used in the test, which constitutes a unique property for the development of
specific but non-toxic antimalarial drugs. Unfortunately, the activity of companeramides against the
parasite is 100-fold lower than that of chloroquine (a commonly used drug), which reduces their
potential utilization.
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However, some molecules show promise as substitutes for antibiotic treatment because of their
strong activity against the parasite. This is the case for hoshinolactam and dolastatins. Hoshinolactam is
an aromatic molecule belonging to the lactam chemical class [182]. It was isolated from an environmental
sample rich in Oscillatoria sp. and has shown antiprotozoal activity against Trypanosoma brucei
(IC50 = 3.9 nM) with no cytotoxicity against MDR-5 (the host cell, IC50 > 25 µM) (Table 5). Furthermore,
the IC50 of pentamidine (another commonly used drug) against Trypanosoma species is 4.7 nM. Thus,
the activity of hoshinolactam is equivalent to that of the antibiotics, and hoshinolactam represents a
promising alternative to pentamidine for Trypanosomiasis treatment [182].
Dolastatins are a well-studied family of peptides. The first members of this family were isolated in
1977 from the sea hare Dolabella auricularia [190]. In 1998, other molecules belonging to the dolastatins
family were isolated from the cyanobacteria Lyngbya majuscula and Symploca hydnoides, which leads to
the hypothesis that dolastatins isolated from the mollusc have a cyanobacterial dietary origin [191].
Dolastin 10, which is one of the dolastatin-related molecules, is the most potent antiprotozoal metabolite
discovered so far from cyanobacteria. This exhibits an IC50 of 0.1 nM (the IC50 of chloroquine is,
on average, 5 nM for the chloroquine-sensitive strain of P. falciparum) [184]. Dolastatins are also
strongly cytotoxic molecules (Table 5). They are able to inhibit tubulin polymerization, which induces
cellular cycle arrest and apoptosis [192]. Antiprotozoal and cytotoxic activities are both the result of
this property. Therefore, there is no apparent specificity for this molecule to act directly against the
parasite itself, where the cellular host is likely the most potent target of dolastatins. For this reason,
Fennel et al. (2003) [184] concluded that dolastatins do not constitute a promising antiprotozoal drug
despite their strong activity.
5.2. Potential Anticancer Activity
Currently, cancers constitute the most important non-transmittable diseases worldwide. According
to the WHO, cancer was the cause of one in six deaths (9.6 million) in 2018 [193]. The annual cost of
cancer in 2010 was estimated to be $1.16 trillion USD [194]. That is why numerous studies have been
conducted to understand the physiology of different cancers and to find new efficient anticancer drugs.
For this purpose, researchers are looking for molecules, and, notably, natural products that are able
to kill cells or inhibit cell proliferation. In this section, we selected some particular cyanobacterial
metabolites for which the mode of action is known as significant examples. We feature metabolites
acting on the microtubule or the microfilament network, histone deacetylase and proteases inhibitors,
and molecules with the ability to reverse multi-drug resistance.
5.2.1. Cytotoxic Activity
The first type of activity test was performed to determine the potential of molecules as anticancer
agents due to cytotoxicity. Different cell lines derived from tumor cells, like the HeLa cell line (derived
from cervical cancer), KB (HeLa derivative), LoVo (human colon tumor), H-460 (human lung cancer),
and MCF-7 (human breast cancer) have been used to assess this activity. Most of the time, the molecules
investigated were tested against two or more cell lines to detect a potent specificity and to evaluate their
potential for drug development. According to this review, 110 families of metabolites isolated from
cyanobacteria showed cytotoxicity, which represents 43% of the molecule families listed in the database.
The best example of potent anticancer molecules derived from cyanobacteria is the dolastatin
family [191]. One synthetic analogue of dolastatin 10, monomethyl auristatin E, is actually used to
treat Hodgkin’s lymphoma in the drug Brentuximab vedotin [191]. Luesch et al. (2001) [187] showed
that dolastatin 10 and symplostatin 1 are 100-fold more efficient than vinblastine (anticancer drug
extracted originally from the Madagascar periwinkle) against the same cell line due to their ability
to depolymerize microtubules. Unfortunately, dolastatins also have strong cytotoxicity [187,195].
Researchers found a way to reduce this toxicity by coupling monomethyl auristatin E with a chimeric
antibody against CD30 (tumor necrosis factor receptor, highly expressed in Hodgkin’s lymphoma)
in order to target only tumor cells [196]. Since then, other antibody drugs linked (ADC) with
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monomethyl auristatin E have been developed. For example, glembatumumab vedotin is currently
under clinical trial. This drug targets GPNMB (glyprotein non-metastatic melanoma protein B), which
is a glycoprotein expressed in melanoma and breast tumors [197]. In addition to the dolastatins,
other cyanobacterial metabolites destabilize the microtubule network. Notably, one such metabolite
is tubercidin, which is a nucleoside produced by Tolypothrix byssoidea, Tolypothrix distorta, Plectonema
radiosum, and Scytonema saleyeriense var. indica [198,199]. This molecule was previously isolated from
the bacterium Streptomyces tubercidicus. Tubercidin has shown inhibition of cell proliferation with an
IC50 of 248 nM (Table 6). Tubercidin acts against dolastatins showing a microtubule stabilizing activity
comparable to taxol bioactivity [200]. Its cytotoxicity is due to its stabilizing property, which causes
mitotic arrest at G2/M transition and stops growth [201].
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Table 6. Cytotoxic metabolites extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Tubercidin Nucleoside -Cytotoxic-Microtubule stabilizer
Tolypothrix byssoidea H-6-2,
Scytonema saleyeriense var. indica CV-14-1,
Plectonema radiosum DF-6-1,
Tolypothrix distorta BL-11-2
[198–200]
Aurilides Depsipeptide
-Cytotoxic
-Lethal activity
-Anti-swarming
-Antiprotozoal
-Induce loss of microfilament network
Lyngbya majuscula,
Okeania sp.,
Lyngbya sp.
[70,202–205]
Swinholide-type Macrolide -Cytotoxic-Actin microfilament disruption
Symploca sp.,
Geitlerinema sp.,
Nostoc sp. UHCC0451,
Phormidium sp.
[206–208]
Anabaenolysins Lipopeptide
-Cytotoxic
-Antifungal
-Hemolytic activity
-Ability to permeabilize cell membranes
Anabaena sp. XPORK 15F,
Anabaena sp. XSPORK 27C [209,210]
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Another mechanism of cytotoxicity noted from cyanobacterial metabolites is the destabilization of
actin microfilaments. As tubulin microtubules, actin microfilaments are key cytoskeleton components
of cells. Microfilaments are involved in several mechanisms: cell division (cytokinesis), cell motility,
cell adhesion, exocytosis, and endocytosis [211]. Thus, molecules with actin-modulating activity are
sought in order to develop anticancer drugs because of their ability to induce apoptosis [211]. Four
cyanobacterial metabolite families have shown disrupting activity of the actin microfilament network:
the lyngbyabellins, the majusculamides, the aurilides, and the swinholide-like molecules (Table 6).
Lyngbyabellins and majusculamides, as mentioned above, have shown antifungal activity
that likely corresponds to their ability to modulate actin polymerization [150–152,165]. Aurilides
are cyclic depsipeptides, and the first member of this family was isolated from the sea hare
Dolabella auricularia [212]. Since then, seven other related molecules have been isolated from
two cyanobacterial genera: Lyngbya and Okeania [70,202–205], and one from Philinopsis speciosa
(cephalaspidean mollusc) [213]. Aurilides showed nanomolar cytotoxic activity associated with a
moderate toxicity to Artemia salina. Two analogues, lagunamides A and B, have also shown antimalarial
activity and anti-swarming activity against Pseudomonas aeruginosa [203] (Table 6). Han et al. (2006) [202]
showed that aurilides induce microfilament disruption at the micromolar level. They concluded that
this disrupting activity is likely related to their toxic and antimicrobial activities.
Swinholide-type molecules were macrolides, originally isolated from the sponge Theonella
swinhoei [214]. In 2005, Andrianasolo et al. (2005) [206] succeeded in isolating swinholide A and two
new related molecules (ankaraholides A and B) from two cyanobacteria (Symploca sp. and Geitlerinema
sp., respectively), which leads to the hypothesis of a symbiotic origin of the compounds isolated
from the sponge [206] (Table 6). More recently, Humisto et al. (2018) identified the swinholide
biosynthetic cluster in Nostoc sp. (Table 6) [207], and Tao et al. (2018) isolated nine swinholide-related
metabolites from a marine Phormidium sp. [208]. Swinholide A, isolated from the marine sponge,
showed microfilament-disrupting activity by stabilizing actin dimers [215]. In addition to their
cytotoxic activity, cyanobacterial swinholides also showed the same actin-disrupting activity, which is
of interest for the development of related anticancer drugs [206].
Other metabolites with noticeable cytotoxicity are anabaenolysins, which are lipopeptides isolated
from two strains of the Anabaena genus [210] (Table 6). Anabaenolysins showed cytotoxicity against
all of the 10 cell lines tested, with LC50 values between 4 and 20 µM depending on the cell lines
and the anabaenolysin variants [210]. In addition, using a trypan dye exclusion assay, these authors
showed that anabaenolysins have a unique profile. Instead of excluding the dye, cells showed an
influx of trypan dye, which means that anabaenolysins permeabilize cell membranes until necrotic
death [210]. Anabaenolysins are able to solubilize the lipid component of the cell membrane, and
likely acts with the same mechanism as the detergent digitonin. Anabaenolysins particularly target
cholesterol-containing membranes and do not induce permeabilization of mitochondria membranes.
As detergents, anabaenolysins also show hemolytic activity, but at lower concentrations than digitonin
and surfactin [209]. In addition, Oftedal et al. (2012) showed that the permeabilization ability of
anabaenolysins also allows the internalization of nodularin [209]. This property is of interest for the
development of a drug administration strategy involving anabaenolysins as a synergistic compound
and other bioactive molecules that cannot be passed through the membrane within the targeted
cells alone.
Six cyanobacterial families of compounds showed the ability to reverse multi-drug resistance (MDR)
in addition to their cytotoxic properties. These include the cryptophycins [216–219], the hapalindole-like
metabolites [116], hapalosin [220], the patellamides [221,222], the tolyporphins [223,224], and
the westiellamide-like [126] molecules (see Supplementary Data S3). Among them, five families
displayed MDR reversal activity by acting on the P-glycoprotein pumps (except for cryptophycins and
patellamides for which the MDR reversal mechanisms have still not been described). P-glycoprotein is
a glycosylated transmembrane protein that transports drugs and toxins out of the cell. This protein is
often overexpressed in cancer cells and leads to resistance against standard chemotherapeutics because
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of its lower accumulation in targeted cells [225]. Thus, metabolites with the ability to inhibit this eﬄux
pump are of interest for developing anticancer drugs or to supplement current chemotherapeutic
strategies in order to increase their efficiency on resistant cancer cells.
5.2.2. Protease Inhibitory Activity
Proteases are a widespread family of enzymes found in most, if not all, organisms. They are
involved in a large number of pathways including coagulation, inflammation, digestion, hemostasis,
and blood pressure regulation [226,227]. There are several types of proteases that are classified by their
specific hydrolysis mechanisms. The major groups are the metalloproteinases, the serine proteases,
the cysteine proteases, the threonine proteases, and the aspartic acid proteases [227]. Because of
their ubiquity, these enzymes are attractive targets for the development of new drugs against diverse
diseases [226]. Some proteases have also shown the potential to act against thrombotic diseases [226],
hypertension [227], pulmonary diseases [228], asthma [229], pathogenic microorganisms [230,231],
and even cancers [227,232]. According to our investigation, 24 families of metabolites presenting
diverse protease inhibitor activities have been isolated from cyanobacteria to date. These compounds
have shown inhibitory activity against a wide range of proteases, including enzymes belonging
to the cathepsin family or the well-known serine proteases trypsin, chymotrypsin, and thrombin.
Only three metabolite families have shown an inhibitory activity against cathepsins. Cathepsins
are frequently overexpressed in cancer cells and are involved in tumorigenesis, cell invasion, and
metastasis [233–238]. One of these three families, the spumigins, isolated from Nodularia spumigena
and Anabaena compacta [239–241], is a set of linear peptides that are structurally similar to the
aeruginosins (Table 7). They showed inhibitory activity against several proteases including trypsin,
thrombin, plasmin, and cathepsin B [240]. All of these proteases are potentially involved in cancer cell
processes, and, notably, cathepsin B has been proposed to be a promising target for anticancer drug
development [234,242].
Table 7. Serine protease inhibitor metabolites extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Spumigins Peptide -Proteasesinhibitory activity
Nodularia spumigena AV1 &
CCY 9414,
Anabaena compacta NIES-835
[239–241]
Cyanopeptolin-like Depsipeptide
-Protease inhibitory
activity
-Other enzyme
inhibition
-Cytotoxic
-Lethal
-Antibacterial
-Antifungal
-Antiprotozoal
Microcystis sp.,
Microcystis aeruginosa,
Aphanocapsa sp.;
Microchaete loktahensis,
Planktothrix agardhii,
Scytonema hofmanni,
Lyngbya sp.,
Lyngbya confervoides,
Lyngbya spp.,
Lyngbya semiplena,
Microcystis viridis,
Dichothrix utahensis,
Nostoc sp.,
Nostoc minutum,
Planktothrix rubescens,
Lyngbya majuscula-
Schizothrix sp. (Assemblage),
Stigonema sp.,
Symploca sp.,
Symploca hydnoides,
Nostoc insulare
[30,31,159,185,186,
188,243–292]
Carmaphycins Peptide
-Protease inhibition
-Cytotoxic
-Antiprotozoal
Symploca sp. WHG
NAC15/Dec/08–5 [293,294]
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Another example of metabolites with interesting activity is the cyanopeptolin-like family. This
family is the second in terms of the number of structural analogues isolated, after the microcystins
(respectively 140 and 246 molecular variants described so far). Currently, more than 50 papers have
reported on the isolation and activities of these metabolites. They are cyclic depsipeptides isolated
from 12 different cyanobacterial genera (Table 7). Among the large number of analogs, a wide range
of activity has been reported for these cyanobacterial metabolites including protease activity and
other types of enzyme inhibition, cytotoxicity, lethal activity, and antimicrobial activity, which open
various possibilities for developing therapies targeting cancer cells or microorganisms or those that
fight some diseases like emphysema [277], pancreatitis [295], or thrombosis [296]. Nevertheless, this
large number of activities can also represent a problem such as how to develop a therapeutic drug
exhibiting a specific activity. It would be interesting to study some analogs in more depth or to conduct
a structure–activity relationship study in order to increase the specificity of synthetic variants.
Lastly, another class of inhibitors that would be of interest for the development of new therapeutics
against tumors is the proteasome inhibitors. Proteasome or ubiquitin-proteasome is a multi-enzymatic
complex of eukaryotes. It is involved in protein degradation in a different way than the lysosomes [296].
Because proteasome catalysis is involved in a wide variety of essential pathways, including cell-cycle
progression and the regulation of apoptosis, it is a potent target for cancer therapy. Moreover,
malignant cells have been shown to be more affected by proteasome inhibitors than normal cells,
which reduce the potentially deleterious side effects of these molecules [232]. Four cyanobacterial
families of metabolites were described to inhibit the 20S core of proteasome: the carmaphycins [293],
the cylindrocyclophanes [169,297–303], the nostocyclopeptides [304,305], and nostodione [306,307]
(see Supplementary Data S3). Among them, the most efficient 20S proteasome inhibitors are the
carmaphycins, which exhibit an IC50 of around 2.5 nM [293], whereas the other compounds present
a micromolar range of action [169,305,306] (Table 7). Only two carmaphycin variants (A and B)
have been isolated from Symploca sp., so far. These molecules are linear peptides with cytotoxic and
antiprotozoal activities. They show the additional ability to inhibit the 20S proteasome activity in yeast
and Plasmodium by interacting with the β5 subunit [293,294]. These bioactivities are interesting for
the use of carmaphycins as anticancer or antimalarial therapeutics. Two studies were conducted to
enhance the specificity of carmaphycins for either applications. To develop a specific antimalarial
drug, LaMonte et al. (2017) synthesized synthetic analogues of carmaphycin B and identified one
analog with a selectivity index of 380 for antiprotozoal activity over cytotoxic activity [294]. On the
other hand, Almaliti et al. (2018) studied the potential of carmaphycins as anticancer drugs and as an
antibody–drug conjugate (ADC) in order to enhance the selectivity of the molecules for cancer cells
and to reduce the potential side effects [308].
Therefore, cyanobacterial metabolites with protease inhibition activities were shown to be less
specific for further use, but the synthesis of synthetic analogs increased the selectivity of some of
these molecules.
5.2.3. Histone Deacetylase Inhibitors
Histone deacetylases (HDACs) are enzymes involved in re-modeling the chromatin and the
acetylation/deacetylation of histone and non-histone proteins. Furthermore, histone deacetylases play
a key role in histone–DNA interactions and in the binding to transcription factors. HDACs have also
been identified as potent regulators of gene expression [309,310]. Because cancer generally emerges
from genetic mutations inducing hyperactivation of oncogenes or loss of tumor-suppressor genes,
targeting mechanisms that are involved in the epigenetic regulation of genes is a promising strategy
for the development of anti-tumor drugs [310].
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Table 8. HDACs inhibitor metabolites extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Largazole Depsipeptide
-Histone deacetylases
inhibitor
-Cytotoxic
-Other enzyme inhibition
-Pro-drug
Symploca sp. [311–316]
Santacruzamate A Carboxylic acidderived
-Histone deacetylases
inhibitor
-Cytotoxic
Symploca sp.
PAC-19-FEB-10-1 [317]
Two molecules showing histone deacetylase inhibitory activity have been isolated from
cyanobacteria so far, which are known as largazole and santacruzamate A. Both of these molecules
come from Symploca sp. strains (Table 8). Largazole has shown inhibition against 12 class I HDACs in
addition to inhibition of the ubiquitin-activating enzyme (E1). It has also shown cytotoxicity to several
cell lines (Table 8). Largazole acts as a pro-drug—the molecule needed to be activated by hydrolysis to
release its active form, the largazole thiol [309]. Santacruzamate A has also shown histone deacetylase
inhibition and cytotoxicity. It shares some structural features with suberoylanilide hydroxamic acid
(SAHA), which is a clinically approved HDAC inhibitor that is used to treat refractory cutaneous T-cell
lymphoma [317]. Salvador-Reyes and Luesch (2015) performed an in-depth review of the activities and
mechanisms of action of these two metabolites [309]. They highlighted the high potency of largazole in
anticancer drug development, while the potency of santacruzamate seems to remain more limited.
5.3. Anti-Inflammatory and Antioxidant Activity
In this section, we specifically describe cyanobacterial metabolites that showed no cytotoxicity
associated with their anti-inflammatory or antioxidant properties.
5.3.1. Anti-Inflammatory Activity
According to our review, seven metabolite families isolated from cyanobacteria were found to
have anti-inflammatory activity (aeruginosins, coibacins, honaucins, malyngamides, phycocyanin,
scytonemin, and tolypodiol).
Currently, anti-inflammatory molecules have been widely studied in order to develop new
therapeutics directed against chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis,
chronic obstructive pulmonary disease, multiple sclerosis, and inflammatory bowel disease [318].
Anti-inflammatory compounds can also be useful against cardiovascular diseases, such as
atherosclerosis [319], and neurodegenerative diseases like Parkinson’s disease [320].
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Table 9. Anti-inflammatory metabolites extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Aeruginosins Peptide
-Anti-inflammatory activity
-Protease inhibitor
-No cytotoxicity
Microcystis aeruginosa NIES-98, NIES-298, NIES-101, NIES-89.
Microcystis viridis NIES-102 Planktothrix agardhii CYA 126/8.
Nodularia spumigena CCY9414. Nostoc sp. Lukesova 30/93
[62,321–323]
Phycocyanin Peptide
-Anti-inflammatory
-Antioxidant
-Specific inhibitor of COX-2
-No lethality
All [59,64,324–326]
Scytonemin Alkaloid
-Anti-inflammatory
-Enzyme inhibition
-No cytotoxicity
Stigonema sp., Nostoc punctiforme, Anabaena variabilis, Anabaena
ambigua, Aphanocapsa/Synechocystis sp. (assembly), Aulosira
fertilissima, Calothrix sp., Calothrix parietina, Calothrix crustacea,
Chlorogloeopsis sp., Chroococcidiopsis sp., Chroococcus sp.;
Cylindrospermum sp., Diplocolon sp., Entophysalis granulos, Gloeocapsa
sp., Hapalosiphon sp., Hapalosiphon fontinalis; Lyngbya sp.,
Lyngbya aestuarii, Nostoc parmelioides, Nostoc commune, Nostoc
microscopium, Nostoc pruniforme, Phormidium sp., Pleurocapsa sp.,
Rivularia atra, Rivularia sp., Schizothrix sp., Scytonema sp., Tolyothrix
sp., Tolypothrix tenni, Westiellopsis prolifica, Scytonema hoffmani
[65,327–331]
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Anti-inflammatory tests have been performed in vitro or in vivo in mice. For example,
malyngamides have been shown to inhibit superoxide production generated by inflammation-
promoting agents [332], and honaucins inhibit pro-inflammatory cytokine expression [61] in the
murine macrophage cell line RAW264.7. The mouse ear edema assay has been performed in vivo
by observing the resorption of ear edema in the presence of anti-inflammatory compounds, such as
phycocyanin [64], scytonemin [330], and tolypodiol [66], which have shown noteworthy activities by
using this assay.
Three metabolites seem to be particularly interesting according to their specific bioactivity profiles:
the aeruginosins, phycocyanin, and scytonemin, which have not shown any toxicity when tested in vitro
or in vivo. Aeruginosins have shown anti-inflammatory properties using the AlphaLISA assay. They
are able to down-regulate the level of pro-inflammatory mediators (IL-8 and ICAM-1) in stimulated
endothelial cells [62] without affecting the viability of two different cell lines [62] (Table 9). Aeruginosins
have also shown serine protease inhibitory activity against trypsin, thrombin, and plasmin [321],
and their corresponding biosynthetic gene cluster was first identified in Planktothrix agardhii and
Nodularia spumigena (Table 9) [241,322]. Currently, no correlation between serine protease inhibition
and the anti-inflammatory activity of aeruginosins were shown. However, on neutrophils, it has been
shown that some serine proteases (elastase, cathepsin G, and proteinase 3) are responsible for the
conversion and activation of proinflammatory chemokines (and notably, interleukine-8 (IL-8)) and are
able to conserve or enhance the inflammation response [333–335]. In this regard, it will be compelling
to further test whether aeruginosins are capable of inhibiting other serine proteases, notably elastase,
cathepsin G, and proteinase 3, in order to determine whether the down-regulation of IL-8 induced by
the aeruginosins is mediated through serine protease inhibition processes.
Phycocyanin is a phycobiliprotein, constituting one of the major cyanobacterial pigments, together
with the chlorophylls and phycoerythrin. It is involved in light-harvesting and the energy transfer
of phycobilisomes within the outer membrane of thylakoids. In addition, phycocyanin has shown a
wide variety of beneficial properties including antioxidant, anti-inflammatory, neuroprotective, and
hepatoprotective activities [64] (Table 9). Authors of phycocyanin studies have reviewed the main
features of phycocyanin anti-inflammatory mechanisms. Phycocyanin is able to scavenge ROS, has
anti-lipoperoxidative effects, and inhibits cyclooxygenases (specifically COX-2) as well as TNF-α release.
All of these properties are unique from the perspective of new therapeutics development targeting
neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, or Huntington’s disorder,
or as an anti-inflammatory agent [64].
Scytonemin is an alkaloid pigment found in the sheath of some cyanobacteria and, particularly, on
some organisms living in extreme environments [65]. Scytonemin synthesis is mainly induced by UV-A
exposure in order to reduce heating and the oxidative stress [65]. Scytonemin is mainly involved in
photoprotection by UV-absorption [65]. It has also been shown to have anti-inflammatory activity with
no cytotoxicity against non-proliferating cells [65,330,331]. In addition, scytonemin has been shown to
inhibit polo-like kinase 1 (PLK1), which is an enzyme involved in the phosphorylation and activation
of proteins such as cdc25C, which is involved in cell cycle progression and the G2/M transition in the
cell cycle (Table 9). As a consequence, scytonemin can repress cell proliferation [65,330,331]. Therefore,
scytonemin could be a promising compound for use in the development of anticancer therapeutics,
sunscreen agents, or anti-inflammatory drugs.
Last but not least, as mentioned above, ambigol have been shown to inhibit cyclooxygenases.
Cyclooxygenases are enzymes belonging to the oxidoreductase enzymatic class. Two related isoforms,
COX-1 and COX-2 [336], have been discovered so far and are involved in inflammation processes
through the synthesis of prostaglandins from arachidonic acid. Some classical anti-inflammatory
molecules are known to target COX. For example, aspirin, which is the most famous COX inhibitor
discovered so far, is a nonsteroidal anti-inflammatory drug (NSAID) [337]. For these reasons, ambigol
is a promising cyanobacterial anti-inflammatory compound. Nevertheless, further studies are still
needed in order to describe its activities and potential unexpected side effects in-depth [338].
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5.3.2. Antioxidant Activity
Oxidative stress is widely recognized to be implicated in neurodegenerative diseases [339,340],
metabolic disorders [341], hypertension [342], liver diseases [343], and cardiovascular diseases [344].
Thus, antioxidant molecules are required to develop or supplement therapy for reducing the harmful
effects of oxidative stress.
According to our review, only four compounds isolated from cyanobacteria show antioxidant
properties. As mentioned above, this low number in comparison to cytotoxic or antimicrobial
compounds might be due to the fact that this activity has been poorly tested in secondary metabolites
and its testing has generally been limited to pigments or molecules implicated in light-harvesting
or UV protection. Antioxidant activity has been characterized for the carotenoids, chlorophyll, the
mycosporine-like amino acids (MAAs), and the phycobiliproteins such as phycocyanin (Table 10).
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Table 10. Antioxidant metabolites extracted from the database.
Molecule Family Chemical Classes Activity Producing Organisms References
Carotenoids Terpenoid -Antioxidant-Sunscreen All [56,345,346]
Chlorophylls Chlorin
-Photosynthesis
-Antioxidant
-Pro-oxidant (sensitizer for
singlet oxygen production)
All [57,345]
MAAs Cyclohexenone linkedwith an amino acid
-Antioxidant
-Sunscreens
Synechocystis sp. PCC 6803, Gloeocapsa sp.
CU-2556, Aphanothece halophytica, Gloeocapsa sp.,
Euhalothece sp., Microcystis aeruginosa, Arthrospira
sp. CU2556, Lyngbya sp. CU2555, Leptolyngbya sp.,
Phormidium sp., Lyngbya cf. aestuarii, Microcoleus
chthonoplastes, Microcoleus sp., Oscillatoria
spongelidae, Trichodesmium spp., Anabaena sp.,
Anabaena doliolum, Anabaena variabilis PCC 7937,
Nostoc sp., Nostoc commune var. Vaucher, Nostoc
commune, Scytonema sp., Nostoc punctiforme ATCC
29133, Nostoc sp. HKAR-2 and HKAR-6, Nodularia
baltica, Nodularia harveyana, Nodularia spumigena,
Aphanizomenon flos-aquae, Chlorogloeopsis PCC 6912
[58,345,347,348]
Phycocyanin Peptide
-Anti-inflammatory
-Antioxidant
-Specific inhibitor of COX-2
-No lethality
All [59,64,324–326]
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Carotenoids are orange pigments that are localized in the thylakoid membrane. They absorb light
between 400 and 500 nm and are involved in photosynthesis by transferring energy to chlorophyll
through a single-singlet energy transfer mechanism [346,349]. Five carotenoids are found in the
majority of cyanobacteria: β-carotene, zeaxanthin, nostoxanthin, echinenone, and canthaxanthin [345].
In addition to their role in light harvesting, carotenoids act as potent photoprotectant molecules and
show antioxidant activity through ROS scavenging [345,349] (Table 10).
Chlorophylls are the ubiquitous pigments of photosynthetic organisms. Chlorophyll a is the
major isoform used by cyanobacteria with most absorbing light at 660 nm [345]. Chlorophylls are
mainly involved in photosynthesis, but they have also shown antioxidant activity in vitro via radical
scavenging and, on the contrary, singlet oxygen production under high light conditions, which mitigates
their potential use as antioxidant therapeutics [345] (Table 10).
Mycosporine-like amino acids (MAAs) are pigments that are widely produced by cyanobacteria
(Table 10) and other algae [58,345]. They absorb light in the UV-A and UV-B ranges with a maximum
absorbance between 310 and 360 nm [58]. The primary function of MAAs is to protect cells from
damage by absorbing UV and to dissipate energy without generating ROS [345,348]. In addition,
MAAs show other unique properties. They have been demonstrated to have antioxidant activity
through ROS scavenging, are able to protect skin from UV damage, and are involved in osmotic
regulation, desiccation, and defense against oxidative and thermal stresses. They are also able to
protect fibroblasts against UV-induced cell death [58,348]. Jain et al. (2017) stated that two products
containing MAAs have been commercialized as sunscreen agents for cosmetics and for use in plastics,
paints, and varnishes as a photo stabilizer [58].
Lastly, as mentioned above, phycocyanins are antioxidant molecules with the ability to scavenge
ROS. In addition to their anti-inflammatory activity, this antioxidant property increases the potential of
phycocyanins to be used for pharmaceutical applications [325].
5.4. Other Metabolites with Potential Beneficial Properties
To close this review on the beneficial activities demonstrated for cyanobacterial metabolites, we
highlight a few other compounds that are of potential interest for various fields of application because
of their specific features.
For instance, grassystatins-tasiamides constitute a depsipeptide group of related compounds
isolated from Lyngbya and Symploca tropical species [350–356]. These metabolites have shown protease
inhibitory activity against cathepsin D, cathepsin E, and the β-amyloid precursor protein-cleaving
enzyme A (BACE1) for tasiamides B and F [350,351] (Table 11). In addition, these compounds have
shown moderate or no cytotoxicity at concentrations higher than required for protease inhibitory
activity [353,354,356]. Cathepsin D is an aspartic protease that is localized in the lysosome. This
enzyme is considered a biomarker of some forms of metastatic breast cancer because of its related
overexpression [236]. Cathepsin D has also been shown to promote proliferation and metastasis [236].
Cathepsin E, being also an aspartic protease, is mainly localized in immune system cells and, notably, in
antigen-presenting cells [357]. Grassystatin A induces the reduction of antigen presentation in dendritic
cells [352], which is correlated with the involvement of cathepsin E in this process and has led to the
hypothesis that grassystatin could modulate the immune response. Alzheimer’s disease pathogenesis
is mediated by the accumulation of amyloid β peptide (Aβ) in the brain. BACE1 is responsible for
Aβ formation by cleaving the amyloid precursor protein (APP). As a result, BACE1 inhibitors could
be promising targets for the development of new therapeutics against Alzheimer’s disease [351,358].
Considering these activities, we assume that members of the grassystatins-tasiamides family constitute
promising components for the development of antiproliferative agents, immune response modulatory
compounds, and therapeutics for Alzheimer’s disease treatment.
During the process of database construction, we noticed that five metabolite families showed
a remarkable ability to bind to cannabinoid receptors (CB1 and CB2). These metabolites were
grenadamide [359], the semiplenamides [360], serinolamide A [361], mooreamide A [362], and the
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columbamides [363]. CB1 and CB2 are cell membrane receptors that belong to the endocannabinoid
system (ECS), which is an important part of the human physiological system. It is involved in a
wide range of different processes, such as brain plasticity, memory, nociception, appetite regulation,
the sleep–wake cycle, the regulation of emotions and stress, and addiction. This ubiquity for the
regulation of various vital processes makes exogenous CB1 and CB2 ligands attractive as modulators
of this system for the management of pain, diabetes, obesity, cancer, epilepsy, or Alzheimer’s disease,
or to develop new anxiolytics [364,365]. Columbamides are the most potent CB1/CB2 ligands from
cyanobacteria discovered so far (Table 11) [363]. They are linear acyl amides that have been isolated
from Moorea bouillonii PNG05-198 using a genome mining approach [363]. To date, only the CB1-binding
and CB2-binding activity of columbamides has been tested, and other investigations are required in
order to look deeper into the activity profiles of these molecules, since they still remain promising
compounds for therapeutic developments.
Table 11. Other metabolites extracted from our database with promising biomedical potential.
Molecule Family Chemical Classes Activity Producing Organisms References
Grassystatins-
Tasiamides Depsipeptide
-Protease inhibitory activity
-Cytotoxic
-Reduce antigen presentation in
dendritic cells
Lyngbya confervoides,
Symploca sp.,
Symploca sp. NHI304,
Lyngbya sp. NIH399
[350–356]
Columbamides Acyl amide -CB1 and CB2 ligands Moorea bouilloniiPNG05-198 [363]
6. Conclusions
In this review, all available information concerning the beneficial activities of natural products
of cyanobacteria was gathered. To write this review, a molecular database of the various families of
metabolites isolated from cyanobacteria was constructed from the systematic analysis of 670 articles.
The derived database represents 260 families of metabolites. It groups various types of information
concerning the taxonomy of producing strains, the respective chemical classes, the origin strain
habitats, and the tested/demonstrated activities for each member of the family, together with the related
full references.
According to this review, from the above 300 different genera of cyanobacteria (referenced by the
taxonomy published by Komarek et al. in 2014) [27], 90 have, so far, been reported to produce bioactive
metabolites. Some of them have been shown to produce a high number of compounds, such as those
from the genus Lyngbya-Moorea, which includes 85 families of metabolites isolated so far. However,
the Lyngbya genus is a polyphyletic group and its taxonomy position is under revision. This number
might be re-evaluated and distributed within distinctive new genera. The genomes of the producing
strains are not available in the majority of cases, whereas Shih et al. (2013) demonstrated the large
genomic potential of numerous cyanobacteria thanks to the biosynthetic pathways of metabolites
highlighted by genome mining analyses [49]. Therefore, the potential for the discovery of new natural
molecules and new biosynthetic pathways from cyanobacteria still remains very important and needs
to be systematically explored.
Cyanobacterial metabolites belong to 10 chemical classes (including peptides, alkaloids, terpenes,
and lipids), where most of the families of metabolites are peptide derivatives (above 50% of the
families). Fourteen different types of activities can be distinguished for cyanobacterial metabolites
(e.g., antimicrobial, lethality, cytotoxicity, and antioxidant). The large majority of the components are
cytotoxic (110 families), whereas some activities have only been tested rarely, and their occurrence
appears to be weakly demonstrated. Globally, no clear correlation has been observed between chemical
classes and the specificity of the respective types of bioactivity. Further studies are needed in order to
precisely understand the mechanisms of action of cyanobacterial metabolites, which potentially links
bioactivity with structural features in order to support the new hypothesis on the biological function of
the production of these components for organisms.
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Lastly, 47 metabolites isolated from cyanobacteria that present remarkable interest for diverse
fields of application were investigated further in the present literature review. For example, hassallidins,
which show specific antifungal activity without antibacterial activity, and scytonemin, which has
anti-inflammatory properties with no cytotoxicity, were detailed. These metabolites are potentially
useful for the development of new concrete applications for cyanobacterial natural products and
illustrate the interest in cyanobacteria as a prolific source of bioactive molecules.
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